Back to Agenda
ON DEMAND - Real World Use of Real World Evidence
Session Chair(s)
Christopher Marrone, PharmD, RPh
Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)
Eli Lilly and Company, United States
Real world evidence (RWE) is playing a significant role in healthcare. RWE is utilized to help make coverage decisions, develop guidelines, and better inform treatment decisions. Regulatory bodies rely on RWE for post-marketing surveillance, assessment of effectiveness as well as to aid the regulatory decision process. The design of clinical trials is being informed by real world evidence. Further, value propositions for pharmaceutical products are being driven by evidence generated from claims and electronic medical records. This session will help the audience gain an appreciation for how RWE is being practically utilized in healthcare today, as well as the outlook for RWE use in the future.
Learning Objective : Describe d practical applications of real world evidence (RWE) in today’s healthcare and regulatory environments; Discuss how RWE can be generated to maximize its utility
Speaker(s)
Framework for Evaluating Real World Data and Real World Evidence for Use in Regulatory Decisions
Nirosha M. Lederer, PhD, MS
Aetion, United States
Head, US Government Partnerships; Senior Director, RWE Strategy
Current and Future Trends in Utilization of Real World Evidence
Edmund Joseph Pezalla, MD, MPH
Enlightment Bioconsult, LLC, United States
Chief Executive Officer
Innovations in Real World Evidence Generation
Imad Al-Dakkak, DMD, MPA, MPH
Alexion Pharmaceuticals, Inc., United States
Associate Director
Have an account?